Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Prices $8M Public Offering

NEW YORK (GenomeWeb) – Molecular diagnostics developer CombiMatrix announced today that it has priced an underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at $1,000 per unit.

The firm hopes to raise gross proceeds of $8 million, part of which it will use to repurchase and retire its Series E convertible preferred stock. The offering is expected to close on or about March 24. Ladenburg Thalmann & Co. served as the sole bookrunning manager and Aegis Capital served as lead manager for the transaction.

Each unit of Series F stock being offered to the public is convertible into approximately 258.4 shares of common stock at a conversion price of $3.87 per share, and 258.4 warrants each to purchase one share of common stock at an exercise price of $5.17 per share. In total, the Series F convertible preferred stock is convertible into nearly 2.1 million shares of common stock, CombiMatrix said.

The company's shares fell 19 percent to $4.35 in Monday morning trading on the Nasdaq.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.